* 
      * 
      * 
      * Approach
      * People
      * Portfolio
  * Careers
  * News
  * Contact
  * Approach
  * People
  * Portfolio
  * Careers
  * News
  * Contact

    Discover.
    Launch.
    Build.
    Transform.

    ● Recent Highlights

    Element Science

    Element Science receives FDA approval for the revolutionary Jewel® Patch Wearable Cardioverter Defibrillator. This milestone marks the beginning of a new era in protecting individuals at temporary risk of sudden cardiac arrest — with a device designed not just to save lives, but to do so without interrupting them.

    Portfolio

    Merida Biosciences

    Merida is advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminate their pathogenic drivers. This approach, enabled by advances in protein engineering and immunology, has the potential to address numerous autoimmune and allergic conditions that are inadequately treated today.

    Merida Biosciences

    Trace Neuroscience

    Trace Neuroscience is a biopharmaceutical company on a mission to expand the promise of genomic medicine for people living with neurodegenerative diseases.

    Trace Neuroscience

    Candid Therapeutics

    Candid Therapeutics is a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases.

    Candid Therapeutics

    Marea Therapeutics

    Marea Therapeutics is a clinical-stage biotechnology company that is working to develop a new generation of medicines for cardiometabolic diseases.

    Marea Therapeutics

    Seaport Therapeutics

    Seaport Therapeutics is a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry.

    Seaport Therapeutics

    bluebird bio

    The FDA announced the approval of bluebird’s Lyfgenia for the treatment of sickle cell disease. Lyfgenia represents one of the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. SCD is a rare, debilitating and life-threatening blood disorder with significant unmet need. Gene therapy holds the promise of delivering more targeted and effective treatments, especially for individuals with rare diseases where the current treatment options are limited.

            18

          Years

            71

          Portfolio Companies

            23

          Marketed Products

            1

          Priority: Patients

    201 Brookline Ave
    Suite 1401
    Boston, MA 02215
    P (617) 585-2000

    499 Illinois Street
    Suite 110
    San Francisco, CA 94158
    P (415) 766-3600

      * Privacy Policy
      * Terms